AGEN

Agenus Inc

NASDAQ

Add Alert

AGEN

Agenus Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

jondoeuk

04/11/24 7:30 PM

Post #1,190

I expect more dilution is on the way after the R/S. Unless they sell non-strategic assets, which is hardly a sustainable business practice.

Bearish

jondoeuk

04/03/24 9:45 PM

Post #1,189

Re: #1,180: @Denzel-72 - R/S is coming … money down the drain

The co-founder/CEO/Chairman has been for 20+ years pumping the company, telling stories and making promises, all the while getting rich off retail.

Bearish

jondoeuk

03/29/24 8:04 PM

Post #1,188

Re: #1,187: @Paullee - where did you see that ??????

They are proposing a R/S at a ratio of 1-for-20 https://finance.yahoo.com/news/why-agenus-stock-plummeted-nearly-233805990.html

Bearish

Paullee

02/15/24 10:49 AM

Post #1,187

Re: #1,186: @TrendTrade2016 - ALL OUT...REVERSE SPLIT ANNOUNCEMENT

where did you see that ??????

TrendTrade2016 PremiumMember

02/15/24 8:32 AM

Post #1,186

ALL OUT...REVERSE SPLIT ANNOUNCEMENT

TrendTrade2016 PremiumMember

02/15/24 7:40 AM

Post #1,185

AGEN SMALL GAPPER AND ON TARGET TO 1.04

DP1011

02/15/24 12:28 AM

Post #1,184

Interesting, would be nice to see this back over a dollar.

Stumblebum Free

02/14/24 1:31 PM

Post #1,183

Something is cooking …..last week good upward movement and picked up volume 😊

TrendTrade2016 PremiumMember

02/14/24 1:23 PM

Post #1,182

AGEN POPPING HARD TO 1.04

axelvento

02/14/24 9:41 AM

Post #1,181

Re: #1,180: @Denzel-72 - R/S is coming … money down the drain

A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy

Who knows what does the future hold$$$$$$$

Denzel-72

01/18/24 9:32 PM

Post #1,180

R/S is coming … money down the drain

Monksdream PremiumMember

01/18/24 3:03 PM

Post #1,179

Re: #1,178: @TommyBoyTrader9460 - $AGEN

AGEN new 52 week low

TommyBoyTrader9460 Free

12/30/23 9:18 AM

Post #1,178

Re: #1,176: @Doktornolittle - Admin(s) please erase my post # 1170.

$AGEN
https://x.com/hannahadad8890/status/1741101133777486197?s=61

TommyBoyTrader9460 Free

12/27/23 6:08 AM

Post #1,177

Re: #1,168: @stockguard - AGEN Agenus initiated with a Buy at H.C. Wainwright

$AGEN
https://x.com/hannahadad8890/status/1739966219229258048?s=61

Doktornolittle Free

11/21/23 11:08 PM

Post #1,176

Re: #1,170: @Doktornolittle - B Riley would not allow me to view

Admin(s) please erase my post # 1170. I don't think the issues were the fault of B. Riley or ASCO... . Maybe, but it is unclear and not worth having the negativity there for posterity.

Monksdream PremiumMember

10/25/23 4:05 PM

Post #1,175

AGEN new 52 week low

Monksdream PremiumMember

10/22/23 12:37 PM

Post #1,174

AGEN new 52 week low

Monksdream PremiumMember

10/05/23 7:00 AM

Post #1,173

AGEN new 52 week low

Monksdream PremiumMember

10/02/23 2:51 PM

Post #1,172

AGEN new 52 week low

Doktornolittle Free

01/23/23 8:39 AM

Post #1,171

Re: #1,170: @Doktornolittle - B Riley would not allow me to view

... B.Riley psswd is in immediate registration confirmation email. That may not be unusual, but the email subject line gives no indication that it contains a psswd. It gives a warm and fuzzy that your registration did go through, so the reader is not compelled to open the email. The reader already knows they registered and the reader does not yet know that they are going to have to login with a password. May be the usual way to do this, but I don't think it is a good way.

As for ASCO GI. Some say the abstracts were embargoed since late-breaking. Maybe so, but why then did the ASCO website instruct me to login to view the abstract. This is with the abstract already located. This is on the abstract page, which only contains the header at that point. Causes confusion.

Doktornolittle Free

01/19/23 11:00 AM

Post #1,170

B Riley would not allow me to view the recent webcast. ASCO would not allow me to view the recently "released: Abstracts. No PR from the company. This while Yhoo Finance is so controlled and filtered since the recent takeover that no light escapes there either.

If you had a similar experience, please message me and we can join forces for a complaint to the SEC.

More detail:
B Riley has no contact other than their private email system which does not work.
ASCO: Found the abstracts, but they told me that I had to log in to view the abstract beyond the header and authors. I spent 12 hours trying to do that. After many dead end phone calls and emails, I finally got them to allow me to log in. Went back to the abstract and now they tell me, you don't have access to the abstract. A slightly different message than when I was not logged in, but still no access.

I videotaped my efforts to access the webcast and abstracts. I suggest you do the same if you have problems like this in the future.

These are SEC violations.

Where is the SEC on these things? I suspect they could care less, but I want to find out.

Doktornolittle Free

11/11/22 8:21 AM

Post #1,169

SITC Oral Presentation on BOT w/wo BAL tomorrow with about a thousand authors. It is a brief presentation, but there are only 4 such on schedule and they are the last notes of the entire SITC session. It is likely that everybody at SITC who can get to these final presentations will be there. I am no technical expert in these matters, but I am confident that BOT is a big deal for a couple of reasons beyond the data. 1) In a brief presentation after ASCO, there were major league Cancer experts discussing the presented results. Those experts were truly impressed with this activity against cold tumors. I have seen phony looking presentations by small biotech companies, and this was not that. Of that I am certain and will listen to nobody else's opinion about it. 2) Agenus has been touting BOT for years now. They knew from the beginning that they had something very special. For me it is not a great leap of faith to expect big things from BOT w/wo BAL. No posts here in almost a year. None for months at alter forum IV, and alter other forum just went through a huge change. Suddenly no new posts in the last 24 hours in the middle of SITC? I don't thinks so. So far, I give the facelift at hooya a big thumbs down. This is it guys. Your new home.

stockguard Free

12/16/21 8:24 AM

Post #1,168

AGEN Agenus initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Michael King initiated coverage of Agenus with a Buy rating and $12 price target. The company has developed a broad portfolio of promising antibodies and bispecifics covering many validated targets in immuno-oncology, King tells investors in a research note. The company has "struck multiple lucrative development agreements with some of the industry's leading oncology players," adds the analyst.

north40000 PremiumMember

12/06/21 11:09 PM

Post #1,167

Re: #1,166: @investtemp - what was the B Riley target price?

$11 from $12. Buy rating. Analyst has been switching back and forth between $11 and $12. November date on last PT, per GOOGL search.

investtemp Free

12/06/21 3:34 PM

Post #1,166

Re: #1,165: @stockguard - B. Riley bullish on Novavax, Agenus amid Omicron

what was the B Riley target price?

stockguard Free

12/06/21 3:11 PM

Post #1,165

B. Riley bullish on Novavax, Agenus amid Omicron spread.
B. Riley analyst Mayank Mamtani reiterates his sector-level view of the need for at least annual vaccine boosters and there being a durable COVID vaccine market, sharing many of the attributes with an expanding flu market that has been clearly rewarding differentiated vaccine solutions. The analyst views sustenance of multiple vaccine modalities prevailing over an "mRNA takes all" viewpoint. Mamtani has a Buy rating and a price target of $305 on Novavax (NVAX) as Omicron variant-specific development preparedness and COV-Boost data reiterate robust positioning in global, durable COVID-19, and flu markets. The analyst also has a Buy rating and a price target on Agenus (AGEN) as he believes under-the-radar SaponiQx's adjuvant is poised to play a meaningful role in strong expected protein subunit vaccine demand. He keeps a Neutral rating on Vaxart (VXRT), calling it one of the few "investable" COVID-19 vaccine pipeline programs directly tackling the transmission issue.

stockguard Free

11/14/21 4:58 PM

Post #1,164

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
https://finance.yahoo.com/news/agenus-subsidiary-saponiqx-builds-innovative-113000784.html

stockguard Free

11/12/21 7:01 PM

Post #1,163

Will not be in the money until it hits their price, no biggie on this small fry:
SEC Form S-3ASR filed by Agenus Inc.
https://quantisnow.com/insight/2002956?s=s

pipette

11/01/21 11:01 PM

Post #1,162

Re: #1,161: @malice1 - China just shut down yahoo and aol. I

There was an article in Oct 26 did u get that one? Most trading platforms have news with their tickers too.

malice1

11/01/21 9:18 PM

Post #1,161

Re: #1,160: @Jnk - Got it!

China just shut down yahoo and aol. I was on the Yahoo Agen Board. Can anyone keep me updated on any significant news?

Jnk

10/25/21 7:06 PM

Post #1,160

Re: #1,159: @stockguard - Either way i`m only focusing on 1181 now

Got it!

stockguard Free

10/25/21 5:56 PM

Post #1,159

Re: #1,158: @Jnk - Well I just bought a bunch more shares!!

Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.

Jnk

10/25/21 3:27 PM

Post #1,158

Well I just bought a bunch more shares!! Hope it pays out!!

stockguard Free

10/22/21 11:40 AM

Post #1,157

UPDATE: Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes

stockguard Free

10/22/21 8:52 AM

Post #1,156

Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
https://endpts.com/agenus-calls-out-fda-for-playing-favorites-as-it-pulls-cervical-cancer-bla-at-agencys-request/

malice1

09/15/21 11:22 PM

Post #1,155

Re: #1,154: @longboarder7892 - Thank you Dr. Hidalgo for all that you

longboarder have any idea what happened the last two days?

longboarder7892 Free

08/26/21 1:34 PM

Post #1,154

Thank you Dr. Hidalgo for all that you have done here with AGEN in just a few months we went from 2.50 to almost 6.50 and will be helping save lives. I hope your work will do the same for my other company that you are on the board of and the PI of their trial. AGEN is looking great with the BMY investment... mmmm

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Bristol-Myers Squibb Company (NYSE:BMY) and Agenus Inc. (NASDAQ:AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus' proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.

conix

07/05/21 8:41 AM

Post #1,153

Re: #1,151: @JohnLocke101 - https://endpts.com/bristol-myers-bets-big-on-anti-tigit-bispecific-from-age

AGEN Chart

ClayTrader Free

05/18/21 5:47 PM

Post #1,152

* * $AGEN Video Chart 05-18-2021 * *

Link to Video - click here to watch the technical chart video

JohnLocke101 Free

05/18/21 12:12 PM

Post #1,151

Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+

iancnyc

05/18/21 12:08 PM

Post #1,150

thank god i heard on
look at that!!!

moonurneighbor Free

05/18/21 10:02 AM

Post #1,149

Great news!

JohnLocke101 Free

05/18/21 9:18 AM

Post #1,148

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

iancnyc

05/06/21 12:41 PM

Post #1,147

what’s going on with this Turd today?

stockguard Free

04/14/21 2:01 PM

Post #1,146

Agenus 1181 New Cancer Response Data Adds To Conviction
https://seekingalpha.com/article/4419058-agenus-1181-new-cancer-response-data-adds-to-conviction

stockguard Free

04/09/21 11:26 AM

Post #1,145

Agenus Inc. (NASDAQ: AGEN) reported earlier this year that it has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab, Agenus' anti-CTLA-4 antibody, in combination with NLM-001, Nelum's small molecule hedgehog inhibitor, and chemotherapy for first-line advanced pancreatic cancer. "This collaboration with Nelum is an exciting next step in our partnership strategy to broaden combinations and indications with our late-stage checkpoint antibodies," said Julie DeSander, Vice President of Business Development and Alliance Management. "Zalifrelimab, our first generation anti-CTLA-4 antibody, shows promising results alone and in combination with balstilimab, our anti-PD-1 antibody, and offers the potential to expand therapeutic benefit in novel combinations."

stockguard Free

03/10/21 5:10 PM

Post #1,144

Re: #1,143: @moonurneighbor - “These are very exciting results which demonstrate the

May hear further strong points from the presentation.
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
https://www.globenewswire.com/fr/news-release/2021/03/10/2190840/0/en/Agenus-to-Present-New-Clinical-Data-on-AGEN1181-at-AACR-2021.html

moonurneighbor Free

02/10/21 7:02 AM

Post #1,143

“These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody. AGEN1181 is showing activity in difficult-to-treat tumors without the neuroendocrine or significant liver toxicities commonly observed with the currently-approved CTLA-4 antibody ipilimumab,” said Dr. Steven O’Day, Chief Medical Officer

MDizzle

02/09/21 9:23 AM

Post #1,142

Agenus Announces New Responses for AGEN1181

Agenus Announces New Responses for AGEN1181
-- 6 total confirmed objective clinical responses in colon, ovarian, and
endometrial cancers

-- No complement-mediated toxicities reported

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed objective clinical responses from its Phase 1/2 trial of AGEN1181, its next-generation anti-CTLA-4, as monotherapy and in combination with Agenus' anti-PD-1 balstilimab.

"These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody. AGEN1181 is showing activity in difficult-to-treat tumors without the neuroendocrine or significant liver toxicities commonly observed with the currently-approved CTLA-4 antibody ipilimumab," said Dr. Steven O'Day, Chief Medical Officer at Agenus. "The responses seen in patients with ovarian and MSS colorectal cancer are particularly encouraging given the generally low activity seen with immunotherapy in these indications."

The Phase 1 dose escalation trial has had no reports of complement-mediated toxicities. These are severe toxicities associated with first-generation CTLA-4 antibodies. The trial has also defined the optimal combination dose for AGEN1181 +/- balstilimab.

Agenus also presented on the first-ever report of intratumoral Treg depletion with a CTLA-4 antibody in clinical trials at SITC 2020.

The summary of responses with AGEN1181 alone or in combination with balstilimab are as follows:(1)
-- CR in PD-L1(-) MSS endometrial cancer patient (1181 monotherapy)

-- CR by PET in PD-L1(-) MSS endometrial cancer patient (1181 + bal)

-- PR in PD-L1(-) refractory ovarian cancer patient (1181 + bal)

-- PR in colorectal cancer patient (1181 + bal)

-- PR in MSS colorectal cancer patient (1181 + bal) -- new confirmed
response

-- PR in ovarian cancer patient (1181 + bal) -- new confirmed response

AGEN1181 alone and in combination with balstilimab has expanded dosing into colorectal cancer. Phase 2 trials in additional cancer indications are scheduled to commence shortly.

moonurneighbor Free

02/09/21 9:16 AM

Post #1,141

Awesome!
https://investor.agenusbio.com/news-releases/news-release-details/agenus-announces-new-responses-agen1181

Older

Agenus Inc (AGEN)

Followers	89	Posters	228
Posts (Today)	0	Posts (Total)	1190
Created	02/12/02	Type	Free
Moderators

http://www.agenusbio.com/

http://finance.yahoo.com/q/ks?s=AGEN+Key+Statistics

Agenus Inc., a biotechnology company, develops and commercializes immunotherapies for cancer and infectious diseases. It markets Oncophage vaccine for the treatment of adjuvant renal cell carcinoma (kidney cancer). The company also has various product candidates under development, which include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and singles, as well as in Phase II clinical trials for the treatment of Alzheimer's disease. In addition, the company's product candidates under development comprise Prophage, which is in Phase II clinical trials for the treatment of glioma (brain cancer) and pediatric neurological tumors; and HerpV, which is in Phase I clinical trials for the treatment of genital herpes. Further, it has various other undisclosed vaccines in Phase I and II studies. The company was formerly known as Antigenics Inc. and changed its name in January, 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.